Genomma Lab Announces Consolidated Earnings Results for the Third Quarter and Year-To-Date of 2017
October 26, 2017 at 01:00 pm EDT
Share
Genomma Lab announced consolidated earnings results for the third quarter and year-to-date of 2017. For the quarter, the company reported net revenues decreased 25.6% in the third quarter. EBITDA for the third quarter 2017 was MXN 703 million compared to MXN 601 million in the third quarter of 2016. Net income amounted to MXN 258.4 million in the third quarter of 2017, representing an 8.4% margin. Sales was MXN 3.1 billion, a 5.4% year-on-year increase.
For the year to date, the company reported Sales was MXN 9.2 billion.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
